Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A controlled phase II to evaluate the efficacy and safety of RYANODEX in patients infected with SARS-CoV-2

Next Previous
Trial Profile

A controlled phase II to evaluate the efficacy and safety of RYANODEX in patients infected with SARS-CoV-2

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dantrolene (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 17 Apr 2020 New trial record
  • 16 Apr 2020 According to an Eagle Pharmaceuticals media release, initial results are expected in May 2020.
  • 16 Apr 2020 According to an Eagle Pharmaceuticals media release, the company has been in contact with the FDA Coronavirus Treatment Acceleration Program (CTAP) to request potential expedited review of the IND application and aims to begin the clinical trial at Hackensack University Medical Center as soon as possible.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top